ContraVir expands mid-stage study of tenofovir prodrug analog into higher dose

ContraVir Pharmaceuticals broadens its ongoing Phase 2a study evaluating tenofovir exalidex against Gilead Sciences’ tenofovir disoproxil fumarate in patients with chronic hepatitis B virus infection by increasing the highest planned dose to 150 mg/day from 100 mg/day. The 84-subject sequential dose escalation study is assessing once-daily doses of TXL for four weeks against 300 mg of TDF once daily.

Therapy Focus – Immunotherapy Closes In On Triple-Negative Tumors

Celgene admitted as much last week by saying it would not push a promising Abraxane-containing chemotherapy regimen into pivotal trials in this Several studies are already under way, most notably a large first-line phase III trial of Abraxane plus Roche’s anti-PD-L1 antibody Tecentriq. Early data are encouraging, and hopes are high that meaningful survival benefits will emerge in the next couple of years.

DPP IV Inhibitors

… Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market………….. II-5 Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 …

Press release distribution, EDGAR filing, XBRL, regulatory filings

Pfizer Receives Approval in the European Union for Nimenrix in Infants Six Weeks of Age and Older )–Pfizer Inc. announced today the European Commission has approved an expanded indication for Nimenrixa Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express High Levels of PD-L1 )–KEYTRUDA Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express H… )–Madame Tussauds and country superstar Brad Paisley joined forces to pay tribute to Grand Ole Opry legend Little Jimmy Dickens by unveiling his wax figure on the R… )–Manitowoc Foodservice announces SVP, General Counsel and Secretary Maurice Jones retirement; promotes Joel Horn to SVP, General Counsel and Secretary effecti… )–Mitsubishi UFJ Capital, a … (more)

SK Chemicals’ hemophilia drug approved in Canada

SK Chemicals, the biopharmaceuticals unit of South Korea’s SK Group, has obtained regulatory approval to sell its hemophilia treatment in Canada, marking another step forward in breaking into overseas markets. SK Chemicals said Sunday that Health Canada, the country’s drug regulator, has granted marketing and sales approval for Afstyla, a biologic drug for hemophilia developed by SK Chemicals and licensed out to Australian biotech firm CSL Ltd. in 2009.

View Press Release

A Once-Daily Treatment that Demonstrated Comparable Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Tenofovir Disoproxil Fumarate — )–Gilead Sciences, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved Vemlidy 25mg, a once-daily treatment for suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function. Vemlidy is a novel targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of tenofovir disoproxil fumarate 300mg.